en · de · es
nmn-notes.peptides7250.com › Info › Chemical Identity And Natural Sources — Deep Dive

Chemical Identity And Natural Sources — Deep Dive

By Editorial Desk · published 2025-08-04 · last reviewed 2025-09-19 · Info

Everything below concerns Nucleotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-09-19. Numbers and descriptions here follow the published literature rather than marketing material.

Chemical Identity and Natural Sources

Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.

Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.

Biochemical Identity and Pathway Role

Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.

NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.

Nmn at a glance

PropertyValueNotes
Common nameNicotinamide mononucleotideOften abbreviated NMN
Chemical formulaC11H15N2O8PBeta anomer form
Molecular mass334.22 g/molCalculated from formula
CAS Registry Number1094-61-7Beta-NMN
AppearanceWhite to off-white powderTypical laboratory grade

Identity and Biochemical Role

Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.

Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.

Related pages on this site

NMN Background and Metabolism

Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.

Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.

Background and Biochemical Context

In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.

Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.

Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.

Identity And Metabolic Context

Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.

NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.

Reference notes

In terms of inhibitors of intrinsic termination, much is still unknown. One of the few examples that is known is bacteriophage protein 7. This is made up of 3.4A and 4.0A cryo-EM structures of P7-NusA-TEC and P7-TEC. This bacteriophage protein 7 stops transcription termination by blocking the RNA polymerase (RNAP) RNA-exit channel and impeding RNA-hairpin formation at the intrinsic terminator. Furthermore, bacteriophage protein 7 inhibits RNAP-clamp motions. Shortening the C-terminal half-helix of the RNAP slightly decreases the inhibitory activity. These RNAP clamp motions have been targeted by some other inhibitors of bacterial RNAP. These inhibitors include myxopyronin, corallopyronin, and ripostatin. These work by inhibiting isomerization. RNA polymerases in all three domains of life have some version of factor-independent termination. All of them use poly-uracil tracts, though the exact mechanisms and accessory sequences vary. In archaea and eukaryotes, there appears to be no requirement of a hairpin.

According to news reports, the execution of Ronald Bert Smith in the state of Alabama on 8 December 2016 allegedly went awry due to the fact he displayed movement soon after midazolam was injected, although prison staff confirmed twice that he was still unconscious before injecting the two fatal drugs. This controversy again stirred concern among the public regarding the effectiveness of the drug in question. In October 2016, the state of Ohio announced that it would resume executions in January 2017, using a formulation of midazolam, vecuronium bromide, and potassium chloride, but this was blocked by a federal judge. On 26 July 2017, Ronald Phillips was executed with a three-drug cocktail including midazolam after the Supreme Court refused to grant a stay. Prior to this, the last execution in Ohio had been that of Dennis McGuire. Murderer Gary Otte's lawyers unsuccessfully challenged his Ohio execution, arguing that midazolam might not protect him from serious pain when the other drugs are administered. He was pronounced dead without incident in about 14 minutes on 13 September 2017. In April 2017, the state of Arkansas carried out a double-execution, of Jack Harold Jones, 52, and Marcel Williams, 46. Arkansas attempted to execute eight people before its supply of midazolam expired on 30 April 2017. Two of them were granted a stay of execution, and another, Ledell Lee, 51, was executed on 20 April 2017. In October 2021, the state of Oklahoma executed inmate John Marion Grant, 60, using midazolam as part of its three-drug cocktail hours after the U.S.

DPP-4 is a serine protease located on the cell surfaces throughout the body. In plasma, DPP-4 enzyme rapidly inactivates incretins including GLP-1 and GIP which are produced in the intestine depending on the blood glucose level and contribute to the physiological regulation of glucose homeostatis. Active GLP-1 and GIP increase the production and release of insulin by pancreatic beta cells. GLP-1 also reduces the secretion of glucagon by pancreatic alpha cells, thereby resulting in a decreased hepatic glucose production. However these incretins are rapidly cleaved by DPP-4 and their effects last only for a few minutes. DPP-4 inhibitors block the cleavage of the gliptins and thus lead to an increased insulin level and a reduced glucagon level in a glucose-dependent way. This results in a decrease of fasting and postprandial glycemia, as well as HbA1c levels.

The Bushies consistently refused." In 2008, Roy Allison, wrote in International Affairs that there was evidence "that the Russian invasion of South Ossetia and then deeper into Georgia was indeed planned and even expected rather than spontaneous and improvised." However, "the exact timing of the intervention during August–September may not have been of Moscow's choosing, if for example South Ossetian forces were impatient to instigate a conflict in July– August to give Russia a pretext for intervention and could not be effectively controlled". Regarding the events of August 7/8, Allison states that "Moscow's insistence that its forces did not cross the Georgian border until Russian peacekeepers in Tskhinvali were in severe jeopardy has gained quite wide acceptance internationally. The Georgian claim has, however, been strengthened by the release of telephone intercepts (lost for a month in the chaos of combat) indicating that at least part of a Russian armoured regiment had crossed into South Ossetia by late on 7 August." In the light of the Russian occupation of uncontested Georgian territory, Russian claim to be carrying out the peacekeeping mission per the Sochi agreements is described as "increasingly surreal". He noted that "international agreements limited Russia's peacekeeping role in South Ossetia to monitoring the ceasefire, with no provision for peace enforcement".

Sources: en.wikipedia.org

Notes from published material

the reduction of growth hormone and insulin-like growth factor 1 (somatomedin C) in adults with acromegaly who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses severe diarrhea/flushing episodes associated with metastatic carcinoid tumors in adults profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas) in adults

Therapeutic drug monitoring (TDM) is a branch of clinical chemistry and clinical pharmacology that specializes in the measurement of medication levels in blood. Its main focus is on drugs with a narrow therapeutic range, i.e. drugs that can easily be under- or overdosed. TDM aimed at improving patient care by individually adjusting the dose of drugs for which clinical experience or clinical trials have shown it improved outcome in the general or special populations. It can be based on an a priori pharmacogenetic, demographic and clinical information, and/or on the a posteriori measurement of blood concentrations of drugs (pharmacokinetic monitoring) or biological surrogate or end-point markers of effect (pharmacodynamic monitoring). There are numerous variables that influence the interpretation of drug concentration data: time, route and dose of drug given, time of blood sampling, handling and storage conditions, precision and accuracy of the analytical method, validity of pharmacokinetic models and assumptions, co-medications and, last but not least, clinical status of the patient (i.e. disease, renal/hepatic status, biologic tolerance to drug therapy, etc.). Many different professionals (physicians, clinical pharmacists, nurses, medical laboratory scientists, etc.) are involved with the various elements of drug concentration monitoring, which is a truly multidisciplinary process.

At half-neutralization the ratio ⁠[A−]/[HA]⁠ = 1; since log(1) = 0, the pH at half-neutralization is numerically equal to pKa. Conversely, when pH = pKa, the concentration of HA is equal to the concentration of A−. The buffer region extends over the approximate range pKa ± 2. Buffering is weak outside the range pKa ± 1. At pH ≤ pKa − 2 the substance is said to be fully protonated and at pH ≥ pKa + 2 it is fully dissociated (deprotonated). If the pH is known, the ratio may be calculated. This ratio is independent of the analytical concentration of the acid. In water, measurable pKa values range from about −2 for a strong acid to about 12 for a very weak acid (or strong base). A buffer solution of a desired pH can be prepared as a mixture of a weak acid and its conjugate base. In practice, the mixture can be created by dissolving the acid in water, and adding the requisite amount of strong acid or base. When the pKa and analytical concentration of the acid are known, the extent of dissociation and pH of a solution of a monoprotic acid can be easily calculated using an ICE table.

The Industrial Revolution was the major technological, socioeconomic, and cultural change in late 18th and early 19th century that began in Britain and spread throughout the world. During that time, an economy based on manual labour was replaced by one dominated by industry and the manufacture of machinery. It began with the mechanisation of the textile industries and the development of iron-making techniques, and trade expansion was enabled by the introduction of canals, improved roads, and then railways. The introduction of steam power (fuelled primarily by coal) and powered machinery (mainly in textile manufacturing) underpinned the dramatic increases in production capacity. The development of all-metal machine tools in the first two decades of the 19th century facilitated the manufacture of more production machines for manufacturing in other industries. The date of the Industrial Revolution is not exact. Eric Hobsbawm held that it "broke out" in the 1780s and was not fully felt until the 1830s or 1840s, while T. S. Ashton held that it occurred roughly between 1760 and 1830 (in effect the reigns of George III, The Regency, and George IV). The effects spread throughout Western Europe and North America during the 19th century, eventually affecting the majority of the world. The impact of this change on society was enormous and is often compared to the Neolithic Revolution, when mankind developed agriculture and gave up its nomadic lifestyle.

Like agonists, inverse agonists have their own unique ways of inducing pharmacological and physiological responses depending on many factors, such as the type of inverse agonist, the type of receptor, mutants of receptors, binding affinities and whether the effects are exerted acutely or chronically based on receptor population density. Because of this, they exhibit a spectrum of activity below the Intrinsic activity level. Changes in constitutive activity of receptors affect response levels from ligands like inverse agonists. To illustrate, mechanistic models have been made for how inverse agonists induce their responses on G protein-coupled receptors (GPCRs). Many types of Inverse agonists for GPCRs have been shown to exhibit the following conventionally accepted mechanism. Based on the Extended Ternary complex model, the mechanism contends that inverse agonists switch the receptor from an active state to an inactive state by undergoing conformational changes. Under this model, current thinking is that the GPCRs can exist in a continuum of active and inactive states when no ligand is present. Inverse agonists stabilize the inactive states, thereby suppressing agonist-independent activity. However, the implementation of 'constitutively active mutants' of GPCRs change their intrinsic activity. Thus, the effect an inverse agonist has on a receptor depends on the basal activity of the receptor, assuming the inverse agonist has the same binding affinity (as shown in the figure 2).

Sources: en.wikipedia.org

Frequently asked questions

What does NMN stand for?

NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.

Is NMN the same as NAD+?

No. NMN is a precursor that can be converted to NAD+ in cells. NAD+ is the larger dinucleotide that participates in many redox reactions.

Does NMN occur in food?

Small amounts of NMN have been reported in several foods, including certain vegetables and fruits. The measured levels vary, and the significance of dietary intake is not fully established.

What is NMN?

NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It consists of nicotinamide, ribose, and phosphate groups.

Network